Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,470 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism Disorder, Glucose Clear all

Conditions: Hypercholesterolemia, Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions: Asynchronous, eLearning Intervention; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes
Interventions: decaff, caffcoff, caffeine, placebo; Other
Lead sponsor: Brooklyn College of the City University of New York; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Diabetes
Interventions: Soccer-based adaptation to the DPP; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 35 Years to 55 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Non-Insulin Dependent
Interventions: Not listed
Lead sponsor: VeraLight, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: Type 2 Diabetes
Interventions: iCOPE Intervention group; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Diabetes
Interventions: HTI-2088, Placebo; Drug
Lead sponsor: Hengrui Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus
Interventions: Medtable; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 40 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Chicago, Illinois • Peoria, Illinois

Conditions: Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions: Patient-led Insulin (intervention group), Provider-led Insulin (standard care); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pre-diabetes
Interventions: YMCA Produce Rx (YPRx) Program Only (Control), YMCA Produce Rx (YPRx) Program + the Diabetes Prevention Program (DPP); Behavioral
Lead sponsor: Tessa Mork; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type2 Diabetes Mellitus, Obesity
Interventions: 3:1 ratio Ketogenic diet; Other
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2, Electronic Health Record, Primary Health Care, Reproductive Behavior
Interventions: Medication Reconciliation (MedRec) Tool, Provider Alert and Decision Support, PREPSheet, Text Messaging; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus Type 2
Interventions: STRIDE Program; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 44 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet Transplant; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes
Interventions: Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Diabetes
Interventions: GLB Traditional Maintenance (TM), GLB-Carb-focused Maintenance (CF); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: Wosulin R, Novolin R; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Chula Vista, California

Conditions: Type1 Diabetes Mellitus
Interventions: Beta Cell Loss and Immune Function, Immune Function with RNAseq; Diagnostic Test · Other
Lead sponsor: University of Exeter; Other
Eligibility: Up to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes, Diabetic Ketoacidosis
Interventions: this is not an intervention study, MRI; Other · Device
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 16 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Sansum Closed-Loop Artificial Pancreas, Insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, Safety Health Monitoring System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Heart Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 95 Years
Enrollment: 5,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions: Cinematic Virtual Reality Training, Traditional Didactic Lecture; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Athens, Ohio

Search by objective public record fields.

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities

The Acute Effects of Coffee on Glucose Metabolism

Soccer-based Adaptation of the Diabetes Prevention Program

Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus

Point of Service Diabetes Screening Evaluation

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination

A Phase 1, Study to Evaluate HTI-2088 Tablet

Medtable: An Electronic Medical Record (EMR) Strategy to Promote Patient Medication Understanding and Use

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

YMCA Produce Prescription Project (YPRx)

Treatment of Type 2 Diabetes With Ketogenic Diet

Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes

STRIDE: Supporting Early Diabetes Self-Management for Parents

Islet Transplantation for Type 1 Diabetes Mellitus

Pharmacogenomics of GLP1 Receptor Agonists

Evaluation of Group Lifestyle Balance Maintenance Strategies

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.

EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

Evaluation of a Non-invasive Brain Compliance Measurement Device

Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

Using Virtual Reality to Improve Medical Training